BRPI0509595A - processo para a preparação de bissulfato de atazanavir, composto, formulação farmacêutica compreendendo os mesmos e uso - Google Patents

processo para a preparação de bissulfato de atazanavir, composto, formulação farmacêutica compreendendo os mesmos e uso

Info

Publication number
BRPI0509595A
BRPI0509595A BRPI0509595-6A BRPI0509595A BRPI0509595A BR PI0509595 A BRPI0509595 A BR PI0509595A BR PI0509595 A BRPI0509595 A BR PI0509595A BR PI0509595 A BRPI0509595 A BR PI0509595A
Authority
BR
Brazil
Prior art keywords
atazanavir
bisulfate
atazanavir bisulfate
crystals
preparation
Prior art date
Application number
BRPI0509595-6A
Other languages
English (en)
Inventor
Soojin Kim
Bruce T Lotz
Mary F Malley
Jack Z Gougoutas
Martha Davidovich
Sushil K Srivastava
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35310244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0509595(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BRPI0509595A publication Critical patent/BRPI0509595A/pt
Publication of BRPI0509595B1 publication Critical patent/BRPI0509595B1/pt
Publication of BRPI0509595B8 publication Critical patent/BRPI0509595B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/127—Preparation from compounds containing pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PROCESSO PARA A PREPARAçãO DE BISSULFATO DE ATAZANAVIR, COMPOSTO, FORMULAçãO FARMACêUTICA COMPREENDENDO OS MESMOS E USO. A presente invenção refere-se a um processo para preparação do inibidor de protease de HIV bissulfato de atazanavir, no qual uma solução de base livre de bissulfato de atazanavir é reagida com ácido sulfúrico concentrado, em uma quantidade para reagir com menos do que cerca de 15% em peso da base livre, sementes de cristais de Forma A de bissulfato de atazanavir são adicionadas à mistura de reação, e, à medida que os cristais do bissulfato de formem, ácido sulfúrico concentrado adicional é adicionado em múltiplos estágios em taxas crescentes, de acordo com uma equação cúbica, para efetuar a formação de cristais de Forma A de bissulfato de atazanavir. E também fornecido um processo para preparação de bissulfato de atazanavir como material de Padrão C. Uma nova forma de bissulfato de atazanavir é também fornecido, o qual é Forma E3, o qual é um solvato de trietanolato altamente cristalino do sal de bissulfato, a partir de etanol.
BRPI0509595A 2004-05-04 2005-05-03 processos para a preparação de cristais de forma a e de material de padrão c de bissulfato de atazanavir BRPI0509595B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US56804304P 2004-05-04 2004-05-04
US60/568,043 2004-05-04
US60753304P 2004-09-07 2004-09-07
US60/607,533 2004-09-07
US11/119,558 2005-05-02
US11/119,558 US7829720B2 (en) 2004-05-04 2005-05-02 Process for preparing atazanavir bisulfate and novel forms
PCT/US2005/015333 WO2005108349A2 (en) 2004-05-04 2005-05-03 Process for preparing atazanavir bisulfate and novel forms

Publications (3)

Publication Number Publication Date
BRPI0509595A true BRPI0509595A (pt) 2007-10-16
BRPI0509595B1 BRPI0509595B1 (pt) 2019-05-14
BRPI0509595B8 BRPI0509595B8 (pt) 2021-05-25

Family

ID=35310244

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509595A BRPI0509595B8 (pt) 2004-05-04 2005-05-03 processos para a preparação de cristais de forma a e de material de padrão c de bissulfato de atazanavir

Country Status (20)

Country Link
US (3) US7829720B2 (pt)
EP (3) EP1755596B9 (pt)
JP (1) JP5086069B2 (pt)
KR (1) KR101153606B1 (pt)
AU (2) AU2005240622B2 (pt)
BR (1) BRPI0509595B8 (pt)
CA (2) CA2565629C (pt)
CY (1) CY1116919T1 (pt)
DK (1) DK1755596T5 (pt)
ES (1) ES2552219T3 (pt)
HR (1) HRP20150962T2 (pt)
HU (1) HUE026242T2 (pt)
IL (1) IL178965A (pt)
MX (1) MXPA06012612A (pt)
NO (1) NO341013B1 (pt)
PL (1) PL1755596T3 (pt)
PT (1) PT1755596E (pt)
RS (1) RS54284B1 (pt)
SI (1) SI1755596T1 (pt)
WO (1) WO2005108349A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US7829720B2 (en) 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
TWI354569B (en) * 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method
US7642049B2 (en) * 2006-06-30 2010-01-05 Bristol-Myers Squibb Company Method for identifying HIV-1 protease inhibitors with reduced metabolic affects through detection of human resistin polymorphisms
ATE536343T1 (de) 2007-06-12 2011-12-15 Concert Pharmaceuticals Inc Azapeptid-derivate als hiv-protease-inhibitoren
PL2170292T3 (pl) * 2007-06-22 2014-06-30 Bristol Myers Squibb Holdings Ireland Tabletkowane kompozycje zawierające atazanawir
JP2010530889A (ja) * 2007-06-22 2010-09-16 ブリストル−マイヤーズ スクイブ カンパニー アタザナビルを含む錠剤組成物
JP2010530890A (ja) * 2007-06-22 2010-09-16 ブリストル−マイヤーズ スクイブ カンパニー アタザナビルを含む錠剤組成物
ATE503467T1 (de) * 2007-06-22 2011-04-15 Bristol Myers Squibb Co Tablettierte atazanavirhaltige zusammensetzungen
US8552036B2 (en) 2009-01-12 2013-10-08 Hetero Research Foundation Polymorph of atazanavir sulfate
WO2011027324A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Polymorphic forms of atazanavir sulfate
BR112012009857A8 (pt) 2009-10-26 2023-04-11 Merck Sharp & Dohme Composições farmacêuticas sólidas contendo um inibidor de integrase
EP2555757B1 (en) 2010-04-09 2016-05-25 Bristol-Myers Squibb Holdings Ireland Atazanavir sulfate formulations with improved ph effect
US20130224294A1 (en) 2010-09-28 2013-08-29 Ratiopharm Gmbh Dry processing of atazanavir
US20140343290A1 (en) 2011-07-27 2014-11-20 Rakesh Kumar Singh Process for the preparation of atazanavir or its bisulfate salt
US8461347B2 (en) 2011-08-05 2013-06-11 Scinopharm Taiwan, Ltd. Process for preparing form A of atazanavir sulfate
WO2014030173A2 (en) * 2012-08-24 2014-02-27 Laurus Labs Private Limited An improved process for the preparation of atazanavir bisulfate
WO2014036690A1 (zh) * 2012-09-04 2014-03-13 上海迪赛诺化学制药有限公司 制备阿扎那韦硫酸氢盐a型结晶的方法
CA2900705A1 (en) * 2013-02-12 2014-08-21 Cipla Limited Process for preparing atazanavir sulphate
CN114763336A (zh) * 2021-01-14 2022-07-19 威智医药有限公司 一种硫酸阿扎那韦晶型的生产方法
CN115215792A (zh) * 2022-06-27 2022-10-21 江西富祥药业股份有限公司 一种制备阿扎那韦或其硫酸盐的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US658435A (en) * 1900-03-22 1900-09-25 William T Ginn Coal-digger.
US4022776A (en) 1974-01-31 1977-05-10 Otsuka Pharmaceutical Company Limited 5-[1-Hydroxy-2-(substituted-amino)]ethyl-8-hydroxycarbostyril derivatives
US3980637A (en) 1975-03-17 1976-09-14 Bristol-Myers Company Production of amoxicillin
DE3403329A1 (de) 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
JPS6186211A (ja) 1984-10-04 1986-05-01 日本碍子株式会社 セラミックス複合構造体及びその製造法
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
US5158777A (en) 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
CA2068402C (en) 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
US5428048A (en) 1993-11-08 1995-06-27 American Home Products Corporation Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
TW483763B (en) 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
KR100486051B1 (ko) * 1996-04-22 2005-09-09 노파르티스 아게 항바이러스활성헤테로시클릭아자헥산유도체
GB9715896D0 (en) 1997-07-28 1997-10-01 Sca Packaging Ltd Containers
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
AU765128B2 (en) 1999-03-22 2003-09-11 Bristol-Myers Squibb Company Fused pyridopyridazine inhibitors of cGMP phosphodiesterase
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
CA2390557A1 (en) 1999-11-11 2001-05-17 Kyorin Pharmaceutical Co., Ltd. Solid preparations for oral use
ES2487897T3 (es) 2000-01-21 2014-08-25 Novartis Ag Combinaciones que consisten de inhibidores de la dipeptidilpeptidasa-IV y agentes antidiabéticos
US6254888B1 (en) 2000-01-28 2001-07-03 Boehringer Ingelheim Pharmaceuticals, Inc. Method for coating pharmaceutical dosage forms
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
CZ20011726A3 (cs) 2000-05-26 2002-02-13 Pfizer Products Inc. Způsob reakční krystalizace, který umoľňuje řídit velikost částic
IL145106A0 (en) 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US6670344B2 (en) 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
JP2004530676A (ja) 2001-04-18 2004-10-07 ノストラム・ファーマスーティカルズ・インコーポレイテッド 持続放出性薬学的組成物のための新規コーティング
EP1467717A1 (en) 2002-01-15 2004-10-20 Ranbaxy Laboratories Limited Stable pharmaceutical compositions comprising ace inhibitor(s)
KR100456833B1 (ko) 2002-08-01 2004-11-10 주식회사 대웅 아목시실린 및 클라불라네이트를 함유하는 유핵정
TW200534879A (en) 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US20050256314A1 (en) 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US7829720B2 (en) 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US20050288343A1 (en) 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
TWI354569B (en) 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method

Also Published As

Publication number Publication date
KR101153606B1 (ko) 2012-06-11
JP2007536245A (ja) 2007-12-13
WO2005108349A3 (en) 2006-11-02
BRPI0509595B1 (pt) 2019-05-14
US7829720B2 (en) 2010-11-09
CY1116919T1 (el) 2017-04-05
US7838678B2 (en) 2010-11-23
EP1755596A2 (en) 2007-02-28
CA2777216A1 (en) 2005-11-17
JP5086069B2 (ja) 2012-11-28
CA2565629C (en) 2012-07-31
KR20070006935A (ko) 2007-01-11
CA2565629A1 (en) 2005-11-17
DK1755596T5 (en) 2016-05-23
HRP20150962T1 (xx) 2015-10-09
IL178965A (en) 2011-05-31
PT1755596E (pt) 2015-11-19
EP1755596A4 (en) 2010-12-29
AU2010201538A1 (en) 2010-05-13
AU2005240622A1 (en) 2005-11-17
IL178965A0 (en) 2007-03-08
WO2005108349A2 (en) 2005-11-17
HUE026242T2 (en) 2016-06-28
RS54284B1 (sr) 2016-02-29
EP2980074A1 (en) 2016-02-03
ES2552219T3 (es) 2015-11-26
EP1755596B9 (en) 2016-02-10
EP2669273A1 (en) 2013-12-04
US20090203630A1 (en) 2009-08-13
US20110124689A1 (en) 2011-05-26
AU2005240622B2 (en) 2010-02-11
SI1755596T1 (sl) 2015-10-30
AU2010201538B2 (en) 2012-09-06
HRP20150962T2 (hr) 2016-04-08
EP1755596B1 (en) 2015-08-12
PL1755596T3 (pl) 2016-04-29
DK1755596T3 (en) 2015-11-16
NO20065441L (no) 2006-11-27
MXPA06012612A (es) 2006-12-15
BRPI0509595B8 (pt) 2021-05-25
NO341013B1 (no) 2017-08-07
US20050256202A1 (en) 2005-11-17
US8513428B2 (en) 2013-08-20

Similar Documents

Publication Publication Date Title
BRPI0509595A (pt) processo para a preparação de bissulfato de atazanavir, composto, formulação farmacêutica compreendendo os mesmos e uso
TWI343786B (en) Diamine derivative, method for manufacturing the same and plant disease control agent containing the sane as active compound
BRPI0813284A8 (pt) Processo para a preparação de um composto da fórmula (i) e composto
BR0314379A (pt) Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase
CL2004000293A1 (es) Compuestos derivados de dihidrofenantridin-sulfonamidas sustituidas, sus sales; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y su uso en el tratamiento de la diabetes tipo ii, alzheimer, demencia senil, asma, col
BR0113234A (pt) Polimorfos de um análogo de epotilona
BRPI0711121A2 (pt) derivados de benzonitrila substituìdos por glucopiranosila, composições farmacêuticas que contêm tais compostos, seu uso e processo para a sua fabricação
BRPI0409109A (pt) novos compostos
BR112015013085A2 (pt) métodos de síntese de um análogo de prostaciclina
ATE523514T1 (de) Tricyclische triazolische verbindungen
BRPI0410238A (pt) compostos orgánicos
BR112013011593A2 (pt) cristal de derivado de morfinan 7-carbamoíla-6,7-insaturada e método para produzir o mesmo
AR099594A2 (es) Proceso para preparar bisulfato de atazanavir y otras formas
NI201300072A (es) Derivados de heteroarilo como moduladores nachr alfa 7
BRPI0612957B8 (pt) composto, processos de preparação de compostos, composição farmacêutica e uso de um composto
WO2009134531A3 (en) Total synthesis of salinosporamide a and analogs thereof
BRPI0507034A (pt) compostos orgánicos
WO2007117591A3 (en) Total synthesis of salinosporamide a and analogs thereof
UY31460A1 (es) Procedimiento de preparacion de compuestos morfinicos
BRPI0415203A (pt) pentanóis reestruturados, um processo para sua produção e seu uso como agentes antiinflamatórios
BRPI0407282A (pt) Processo para preparação de inibidores de pirrolotriazina cinase
BRPI0508704A (pt) métodos para a preparação de um composto e para a preparação de calcipotriol ou monoidrato de calcipotriol, composto, e, usos de um composto e de éster dietìlico do ácido (2-ciclopropil-2-oxoetil) fosfÈnico
ATE441630T1 (de) Substituierte cyclopenten-verbindungen
Yang et al. Synthesis and antiviral activities of novel gossypol derivatives
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor

Legal Events

Date Code Title Description
B65X Notification of requirement for priority examination of patent application
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/05/2019, OBSERVADAS AS CONDICOES LEGAIS

B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)

Free format text: REQUERENTE DA NULIDADE: ASSOCIACAO BRASILEIRA INTERDISCIPLINAR DE AIDS - 870190118406 - 14/11/2019

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/05/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED COMPANY (CH)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.